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Background: There are few publications on quality measurement of COPD health state according to the severity
level using EQ-5D in Korea. The present study aimed to evaluate the health-related quality of life (HRQoL) in
patients with chronic obstructive pulmonary disease (COPD) in terms of disease severity in Korea.
Methods: Totally two hundred patients with COPD were consecutively recruited in one tertiary hospital of Korea.
Each respondent was asked to fill out the questionnaire through a face-to-face interview after providing informed
consent. The questionnaire included general and clinical characteristics as well as the EQ-5D and Clinical COPD
Questionnaire (CCQ). HRQoL was evaluated according to the Global Initiative for Chronic Obstructive Lung Disease
(GOLD) criteria and severity of breathlessness.
Results: The adjusted mean EQ-5D index scores were 0.83, 0.88, 0.81 and 0.60 in stage I, II, III and IV, respectively.
The EQ-5D index tended to decrease with GOLD criteria. The adjusted mean EQ-Visual Analog Scale (VAS) scores
ranged from 65.1 in stage IV to 73.9 in stage I. The CCQ total scores deteriorated with an increasing GOLD stage
and severity of breathlessness (all P < 0.001). The correlation between CCQ total score and EQ-5D index was −0.69.
Conclusions: Our study shows that HRQoL in COPD measured by EQ-5D and CCQ worsens with the GOLD stage
and severity of breathlessness. EQ-5D and CCQ could be useful instruments for an evaluation of HRQoL in COPD
patients in Korea.
Keywords: Chronic obstructive pulmonary disease, Quality of life, Utility, EQ-5D, CCQBackground
The prevalence and mortality of chronic obstructive pul-
monary disease (COPD), already a leading cause of mor-
bidity and mortality worldwide, is increasing [1]. COPD
prevalence varies considerably across countries and across
different groups within countries, from 3% in India [2] to
19.7% in Uruguay [3]. In Korea, the prevalence of COPD
was recently found to be 13.1% in adults over 40 years of
age and 31.9% in adults over 65 years of age [4]. The
prevalence and mortality of COPD are expected to in-
crease in Korea due to rapid increases in life expectancy.
Because COPD is a chronic condition, patient manage-
ment focuses on improving those symptoms that can ad-
versely affect health status and quality of life [5].
Health-related quality of life (HRQoL) instruments
have increasingly been used in clinical trials and health* Correspondence: jominwoo@amc.seoul.kr
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unless otherwise stated.services research, both as primary and secondary end-
points. The EQ-5D questionnaire is a generic, preference-
based HRQoL instrument that generates utility scores.
These utility scores have been used to compare dis-
ease burden across different conditions and to calcu-
late quality-adjusted life years (QALYs) for the economic
evaluation of health care interventions [6]. The EQ-5D
instrument has been found to be the most frequently
used questionnaire in cost-utility studies, including QALY
studies [7].
A previous review of the psychometric properties of
the EQ-5D supported its construct validity, test-retest
reliability, and responsiveness in studying COPD [5]. An-
other health status measure is the Clinical COPD Ques-
tionnaire (CCQ), which is a self-administered instrument
that measures clinical control in patients with COPD [8].
The CCQ helps clinicians to identify not only the clinical
status of the airways but also activity limitations and emo-
tional dysfunctions in the patients [8]. Also the CCQ is. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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COPD [8,9].
The aim of this study was to evaluate the HRQoL of
COPD patients in Korea using the EQ-5D and CCQ ac-
cording to COPD severity. In addition, we explored cor-
relations between the EQ-5D and both disease-specific
measures and the forced expiratory volume in one sec-
ond (FEV1, the volume exhaled during the first second




This study was approved by the Institutional Review
Board of Asan Medical Center (approval number: 2011–
0119). Two respiratory specialists orally asked their pa-
tients with COPD visiting the outpatient clinics of one
tertiary hospital to participate in the survey. If the pa-
tients wanted to participate in the survey, they were di-
rected to the interview room. All participants provided
written informed consent. A total of 202 subjects with
COPD were consecutively recruited. One of two inter-
viewers (one is first author, the other is research assist-
ant) performed face-to-face interviews according to a
schedule. Two subjects were excluded from analysis be-
cause their pulmonary test results were not available.
Each respondent was asked to fill out the questionnaire
through a face-to-face interview. The survey took ap-
proximately 5 minutes to complete. This survey was
conducted from 7th May 2012 to 18th July 2012. There
was no withdrawal during the survey.
Information
The questionnaire included general and clinical charac-
teristics, the EQ-5D, and the CCQ. Demographic factors
included sex, age, level of education and current smok-
ing status. Clinical characteristic consisted of current
symptoms (cough, sputum, chest pain, dyspnea, weight
loss, fever, and fatigue), the number of admissions dur-
ing the previous year, and the severity of breathlessness.
Patients were asked to describe their severity of breath-
lessness as one of three categories that reflected their
current state: short of breath during strenuous activities,
stopping to catch their breath after a few minutes walk-
ing or breathless when dressing or washing.
The EQ-5D is a generic preference-based measure
where health status is described in terms of five dimen-
sions: mobility, self-care, usual activities, pain/discom-
fort, and anxiety/depression. Each dimension has three
levels, indicating no problems, some or moderate prob-
lems, and extreme problems [6]. The EQ-5D provides a
single index value for health status by applying a formula
that essentially attaches values to each of the levels in
each dimension [10]. The EQ-5D index of health state inthis study was calculated using the valuation set of the
Korean population [11]. Therefore, the possible range of
EQ-5D scores was from −0.171 to 1.0, with 1.0 denoting
full health (11111 state) and 0.0 denoting death. The
EQ-Visual Analog Scale (VAS) records the respondent’s
self-rated health on a vertical, VAS where the endpoints
are labeled ‘Best imaginable health state’ (100) and
‘Worst imaginable health state’ (0) [10].
The CCQ consists of ten items divided into three do-
mains: symptoms, functional states, and mental states.
Subjects are asked to answer based on their experiences
during the previous seven days. Subjects responded to
each question using a 7-point scale where 0 = asymp-
tomatic or no limitation and 6 = extremely symptomatic
or totally limited [9]. Individual items in the CCQ are
equally weighted; thus, the total score and three domain
scores are calculated by averaging the related items (ran-
ging from 0 to 6) [9]. A higher score represents a poorer
health status.
The severity of COPD was categorized by two different
approaches. The first classification of severity was based
on the FEV1 as a percentage of predicted normal values
(FEV1% predicted) from the Global Initiative for Chro-
nic Obstructive Lung Disease (GOLD) guidelines: stage
I = ≥80%; stage II = 50–79%; stage III = 30–49%; and
stage IV = <30% [12]. FEV1 values were retrospectively
obtained from patients’ medical records. FEV1 values mea-
sured at the nearest day of survey date including the visit
day were used. The second criterion was based on the se-
verity of breathlessness in our questionnaire. It was modi-
fied by authors referring to another publication [13].
Analysis
According to these severity criteria, we calculated both
crude means and adjusted least square means of the EQ-
5D index, EQ-VAS and CCQ total scores. Analysis of
covariance (ANCOVA) was performed to calculate the ad-
justed mean of each HRQoL score. The criteria of COPD
severity were used as the factors and age group, gender,
level of education, and smoking status were used as the
covariates. The sensitivity of both the EQ-5D index and
the CCQ scores according to the GOLD stage were ex-
plored using the effect size. The effect size was calculated
as the ratio between the mean score differences between
two consecutive GOLD stages and the pooled standard
deviation (SD, average variation of two groups) [14]. The
effect size was interpreted using Cohen’s criteria [15].
While 0.2 was interpreted as a small magnitude of effect,
0.5 indicated a medium effect, and 0.8 was interpreted as
a large effect.
To explore the convergent validity of EQ-5D in COPD
patients, the correlations between EQ-5D index and EQ-
VAS, CCQ, the disease-specific and clinical measures
and FEV1 were examined using the Pearson correlation




Less than 60 25 (12.5)
60–69 74 (37.0)
70–79 85 (42.5)
80 and more 16 (8.0)
Gender,
Male 183 (91.5)
Level of education, years
6 or below 48 (24.0)
7–9 45 (22.5)
10–12 62 (31.0)










Chest pain 47 (23.5)
Weight loss 40 (20.0)
Fever 14 (7.0)
Reporting of problems in the EQ-5D dimensions
Mobility 99 (49.5)
Self-care 43 (21.5)
Usual activities 88 (44.0)
Pain/discomfort 69 (34.5)
Anxiety/depression 66 (33.0)
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relation between FEV1 and a patient’s health related
quality of life score, while the correlation between EQ-
5D index and CCQ score was moderate to high based
on previous publications [8,9,12]. The internal consistency
of the CCQ was evaluated with Cronbach’s alpha.
Statistical analyses were conducted with the SAS soft-
ware package (version 9.1; SAS, Cary, NC, USA). P < 0.05
was considered to be statistically significant.
Results
A total of 200 out of 202 completed questionnaires were
used to analyze the HRQoL. The characteristics of the
subjects are shown in Table 1. The mean age of the sub-
jects was 68.5 (SD = 9.1) years and 91.5% were male. Of
these, 18 were current smokers and 156 were ex-smokers.
Sputum was the most common symptom for subjects
followed by fatigue and dyspnea. Fifty percent of subjects
reported mobility problems in the EQ-5D. The mean EQ-
5D index was 0.84 (SD = 0.16) and the mean EQ-VAS
score was 69. The mean values of the lung function was
50.7, 56.3, 78.8 in FEV1/FVC, FEV1 Predicted (%), and
FVC Predicted (%), respectively.
The EQ-5D index and EQ-VAS scores by COPD sever-
ity according to GOLD stage are illustrated in Table 2.
The adjusted mean differences in the EQ-5D index and
EQ-VAS scores between the four different groups were
statistically different (P < 0.001, P = 0.033, respectively).
Following post hoc pairwise comparison, the adjusted
mean EQ-5D indices in the stage I, II and III groups were
between 0.81 and 0.88, which were significantly higher
than the 0.60 of the stage IV group (all P values <0.001).
The adjusted mean EQ-VAS scores were 73.9 in stage I
and 65.1 in stage IV. The effect sizes for the EQ-5D index
between stages II and III and stages III and IV were 0.47
and 1.18, respectively, while the corresponding values for
the EQ-VAS were 0.33 and 0.19, respectively.
The CCQ scores by COPD severity according to GOLD
stage are shown in Table 3. All scores for the CCQ signifi-
cantly increased as the COPD stage worsened. In post hoc
analysis, the functional state scores for the CCQ in stage
II were significantly different from those of stages III and
IV (P = 0.003 and P < 0.001, respectively) while the scores
between stages I and II were not significantly different
(P = 0.680). The effect sizes for the CCQ total score be-
tween stages II and III and between stages III and IV
were 0.37 and 0.65, respectively, while that for the CCQ
total score was 0.20 between stage I and stage II.
HRQoL scores according to breathlessness are shown
in Table 4. In all HRQoL scores, quality of life signifi-
cantly worsened as severity of breathlessness increased.
The mean EQ-5D index was 0.87 for subjects who felt
short of breath during strenuous activity, 0.74 for sub-
jects who had to stop to catch their breath after a fewminutes walking, and 0.54 for subjects who were breath-
less when dressing/washing. In pairwise comparison, all
HRQoL score differences by the level of breathlessness
were significantly different except for that of the EQ-
VAS between levels 2 and 3 (P = 0.061). The effect sizes
for the EQ-5D index in breathlessness between the level
1 and level 2 groups and between the level 2 and level 3
groups were 0.55 and 1.14, respectively, while those for
the CCQ total score were 0.60 and 1.45, respectively.
Cronbach’s alpha was 0.88 for the CCQ total items. In-
ternal consistencies of symptom, functional state and
mental state were 0.69, 0.85 and 0.63, respectively. Table 5
shows the Pearson correlation coefficients between the
EQ-5D, CCQ and FEV1% predicted. Correlation coeffi-
cients between EQ-5D index and CCQ instrument ranged
Table 2 EQ-5D index and EQ-VAS scores by GOLD criteria
Crude mean (SD) P value* Adjusted meana (SE) P value† Groupingb
EQ-5D index
Stage I, n = 13 0.83 0.17 <0.001 0.83 0.04 <0.001 A
Stage II, n = 114 0.88 0.12 0.88 0.02 A
Stage III, n = 59 0.82 0.16 0.81 0.03 A
Stage IV, n = 13 0.61 0.26 0.60 0.04 B
EQ-VAS
Stage I, n = 13 71.9 18.9 0.042 73.9 5.4 0.033 A
Stage II, n = 114 71.9 17.8 75.1 2.9 A
Stage III, n = 60 65.0 20.6 68.9 3.3 A
Stage IV, n = 13 60.9 13.9 65.1 5.6 A
SE, standard error of the mean.
*Analysis of variance (ANOVA) tests of whether the four groups are equal.
†Analysis of covariance (ANCOVA) tests of whether the four groups are equal.
aMeans were adjusted by age group, level of education, gender, and smoking status.
bDifferent alphabet (A, B) means a statistically significant difference group after Bonferroni correction. The same grouping was shown in both ANOVA
and ANCOVA.
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CCQ total scores. The correlation between either the EQ-
5D index or CCQ total scores and the FEV1% predicted
was 0.30 and −0.35, respectively.
Discussion
The present study shows that the mean EQ-5D index
decreased as the GOLD criteria stages II–IV (based on
FEV1% predicted) and extent of breathlessness increased.
Lower EQ-5D utility scores were associated with very se-
vere COPD. The difference between moderate and severe
COPD based on the FEV1% predicted value was one-third
of the difference between the very severe and severe states.
However, the utility scores of different COPD severities
were not significantly different except for very severe
COPD. In contrast, based on the severity of dyspnea, the
EQ-5D utility score showed significant differences in all
group comparisons and the corresponding effect size of
patients with different levels of dyspnea ranged from 0.47
to 1.18, which indicated around a medium-to-large effect
based on Cohen’s criteria.Table 3 CCQ scores according to GOLD criteria
N CCQ total score
Sympt
Mean (SE) Mean
Stage I 13 0.8 (0.3) 1.1
Stage II 114 0.9 (0.3) 1.3
Stage III 60 1.4 (0.2) 1.6
Stage IV 13 2.0 (0.3) 1.7
P trend* <0.001 0.026
All CCQ scores [adjusted mean values (SE)] were adjusted by age group, level of ed
*The P–trend value tests the null hypothesis that there is no linear trend between tAlso all CCQ scores significantly increased according
to both the GOLD stage and the severity of breathless-
ness. Our analysis showed that the differences in the
CCQ total scores among GOLD stages were more than
0.4 except between stages I and II. Kocks et al. [16] re-
ported 0.4 as the minimal clinically important difference
of the CCQ total score. The effect sizes for the differences
in the CCQ total scores between GOLD stages II and III
and between GOLD stages III and IV demonstrated the
discriminative capacity of the CCQ measure. The CCQ
items were internally consistent (Cronbach’s alpha = 0.88)
and all CCQ scores were also strongly correlated with the
EQ-5D index. Thus, our results suggest that both the EQ-
5D and CCQ instrument can be valid in measuring
HRQoL in patients with COPD in Korea and that the se-
verity of breathlessness is a more distinguishable criterion
of both HRQoL instruments than the GOLD criteria.
We compared the present findings with studies from
other countries that used the EQ-5D with the UK-based
algorithm to measure the utility scores of patients with
COPD according to GOLD stage. Rutten-van MolkenCCQ domain score
om Functional state Mental state
(SE) Mean (SE) Mean (SE)
(0.3) 0.6 (0.3) 0.4 (0.4)
(0.2) 0.7 (0.2) 0.8 (0.2)
(0.2) 1.3 (0.2) 1.1 (0.3)
(0.3) 2.3 (0.3) 2.2 (0.4)
<0.001 <0.001
ucation, gender, and smoking status. SE, standard error of the mean.
he CCQ means and GOLD stage order.
Table 4 HRQoL scores according to the severity of breathlessness
Level 1, n = 146 Level 2, n = 45 Level 3, n = 7 P trend*
EQ-5D index 0.87 (0.02) 0.74 (0.03) 0.54 (0.06) <0.0001
EQ-VAS 75.07 (2.63) 65.64 (3.46) 52.57 (7.11) <0.0001
CCQ total score 0.82 (0.12) 1.89 (0.16) 3.36 (0.16) <0.0001
CCQ domain score
Symptoms 1.14 (0.13) 1.97 (0.17) 3.56 (0.36) <0.0001
Function 0.58 (0.14) 1.96 (0.19) 3.08 (0.39) <0.0001
Mental 0.65 (0.19) 1.59 (0.25) 3.53 (0.52) <0.0001
Level 1, short of breath during strenuous activities; level 2, stopping to catch breath after a few minutes walking; level 3, breathless when dressing or washing.
All scores [adjusted mean values (SE)] were adjusted by age group, level of education, gender, and smoking status. SE, standard error of the mean.
*The P –trend value tests the null hypothesis that there is no linear trend between the HRQoL scores and severity of breathlessness order.
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scores of 0.787 and 0.73 for moderate, 0.750 and 0.74
for severe and 0.64 and 0.52 for very severe COPD, re-
spectively. A systematic review [5] reported the follow-
ing pooled mean utility scores (SD) according to GOLD
stage: 0.74 (0.66–0.83) in moderate, 0.69 (0.60–0.78) in
severe and 0.61 (0.44–0.77) in very severe COPD. When
our data were applied to UK-based algorithm to calcu-
late the utility scores of patients with COPD, mean util-
ity score plummeted to 0.69, 0.58 and 0.24 for moderate,
severe, and very severe COPD, respectively.
Differences in utility scores by each COPD state be-
tween countries could be due to differently calculated al-
gorithms or subject heterogeneity, in particular in terms
of current symptoms and breathlessness severity that is
regardless of airflow limitation severity. Substantial dif-
ferences in the UK and Korean value sets exist and the
UK algorithm tends to give lower EQ-5D scores than
the Korean algorithm [19]. When we reanalyzed our data
using the UK algorithm, the utility weights of all COPD
health states were lower than those of previous studies.
The CCQ total scores for mild, moderate, severe, and very
severe COPD in the Netherlands were 1.0, 1.3, 1.9 and 2.5,
respectively [8], and those for mild to moderate, severe,
and very severe COPD in Italy were 0.9, 1.4, and 2.6, re-
spectively [9]. As our subjects showed a higher HRQoL in
very severe COPD than previous findings, it could mean
more well-controlled patients were recruited.Table 5 Pearson’s correlation between CCQ, EQ-5D, and FEV1
EQ-5D index EQ-VAS CCQ symptom CCQ f
EQ-5D index 1.00 -- --
EQ-VAS 0.41 1.00 --
CCQ symptom −0.55 −0.43 1.00
CCQ functional state −0.64 −0.50 0.64
CCQ mental state −0.59 −0.42 0.62
CCQ total −0.69 −0.53 0.87
FEV1% predicted 0.30 0.18 −0.22
All correlations are statistically significant.Several studies showed a generally weak association be-
tween changes in FEV1 and the generic HRQoL [20,21].
Our results also showed a low correlation between the
EQ-5D index and the FEV1, whereas the results of Stahl
et al. [18] showed a strong relationship between HRQoL
and an impaired lung function. Even with disease-specific
instruments designed to measure the HRQoL in patients
with obstructive airways disease, such as the St. George’s
Respiratory Questionnaire, the association between the
HRQoL and FEV1 was weak [21,22].
To the author’s best knowledge, no study has been
published yet regarding HRQoL of according to severity
in Korean COPD patients. Our study measured HRQoL
using EQ-5D and CCQ according to COPD severity and
these instruments could be utilized as an outcome meas-
ure in an economic evaluation of COPD intervention
programs or clinical studies in Korea.
Our study has several limitations. First, subjects were
recruited during outpatient visits, reducing the number
of patients with very severe COPD patients. As a result,
the mean utility score of the very severe COPD state was
less precise than that of milder states. Small sample sizes
for the GOLD stage 1 may not represent feature in these
group as well. However, a review study reported zero dif-
ference of pooled EQ-5D utility index between mild to
moderate stages [5]. Second, COPD is characterized by
fluctuations in symptoms and the prevention of exacer-
bation is important in COPD management. However, our% predicted
unctional state CCQ mental state CCQ total FEV1% predicted
-- -- -- --
-- -- -- --
-- -- -- --
1.00 -- -- --
0.64 1.00 -- --
0.90 0.82 1.00 --
−0.36 −0.31 −0.35 1.00
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acerbation, which means that the results of this study are
less useful for patients with exacerbation and that further
research is required regarding the evaluation of HRQoL
in COPD patients with exacerbation. Third, there was
a disproportionate distribution of gender in our study.
Among Korean adults over the age of 40 years, 13.4%
(men, 19.4%; women, 7.9%) had airflow obstruction [23].
Our data could under-represent female compared to the
COPD prevalence by gender. Fourth, only a third of par-
ticipants measured FEV1 on the day of the interview and
others performed pulmonary function test during a previ-
ous visit. FEV1 on the interview date could reflect the bet-
ter quality of life of the day, but changes of FEV1 from a
previous visit were not large due to a chronic feature of
COPD. As a matter of fact, the findings of the subgroup
analysis of the FEV1 that were measured on the day of
interview were similar to the original one. Lastly, the se-
verity of breathless in our study could be regarded as be-
ing somewhat arbitrary. To evaluate the impact of various
symptoms on HRQoL in COPD patients, more standard-
ized criteria (e.g., the modified Medical Research Council
questionnaire, the COPD assessment test) could be used.Conclusions
In conclusion, our results suggest that both the EQ-5D
and CCQ instrument can be valid in measuring HRQoL
in patients with COPD in Korea and that the severity of
breathlessness is a more distinguishable criterion than
the GOLD criteria if both HRQoL instruments are com-
pared. Further research is recommended for estimating
utility in exacerbation.
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